Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
May 20, 2026PamplonaIn recruitmentEarly phase
D798VC00001 Clinical trial to evaluate the safety and efficacy of new interventions and treatment combinations in participants with colorectal cancer
The purpose of this study is to learn more about the effectiveness and safety of the study drug, volrustomig (also known as MEDI5752), when given in combination with a standard treatment for colorectal cancer. -
May 19, 2026PamplonaIn recruitmentEarly phase
2012-0001 A clinical trial in people with advanced cancer to investigate the tolerability of different doses of BI 3819026 when taken alone and in combination with ezabenlimab.
The purpose of this study is to determine the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and in combination with ezabenlimab. -
May 19, 2026Pamplona/MadridIn recruitmentEarly phase
GCT1079-01 A clinical trial to evaluate the safety and preliminary efficacy of GEN1079 in participants with certain advanced solid tumors.
The trial consists of 3 parts. The objective of Part 1 is to assess the safety of GEN1079 at increasing doses and to identify the doses to be used in subsequent phases. The objective of Part 2 is to refine and identify the dose that is effective while causing the fewest side effects. The goal of Part 3 is to further investigate whether GEN1079 works against the tumor and how it does so, and to continue learning about its side effects. -
May 19, 2026Pamplona/MadridIn recruitmentEarly phase
GCT1184-05 A study to evaluate the efficacy and safety of Rina-S in participants with non-small cell lung cancer.
The goal is to continuously monitor your well-being and safety, and to ask you if you have started a new treatment. If, for any reason, the doctor or trial staff are unable to contact you, a family member may provide information about your condition, or the trial doctor may obtain it from sources such as your medical records, national or local registries, or publicly available information, as permitted by local regulations. -
May 13, 2026Pamplona/MadridIn recruitment
42756493BLC3004 Clinical trial to evaluate the efficacy and safety of the TAR-210 erdafitinib intravesical delivery system compared with intravesical chemotherapy as monotherapy in patients with non-muscle-invasive bladder cancer
The main objective of this study is to compare disease-free survival (DFS) between patients receiving TAR-210 and investigator-selected intravesical chemotherapy. -
May 13, 2026Pamplona/MadridIn recruitmentEarly phase
IMC-P115C-1005 Phase I clinical trial of IMC-P115C in participants with PRAME-positive advanced cancers.
The main objective is to evaluate the safety and tolerability of IMC-P115C as monotherapy and in combination in participants with PRAME-positive advanced tumors, and to identify the MTD (maximum tolerated dose) and dosing regimens (combination of IMC-P115C dose, dosing frequency, and premedication) for further optimization. -
May 13, 2026Pamplona/MadridIn recruitmentEarly phase
PED-DNX2401 Trial of intratumoral administration of DNX-2401 for the treatment of high-grade, recurrent or refractory brain tumors in pediatric patients or young adults
The main objective of this trial is to assess the efficacy or antitumor effect of a virus called DNX-2401 in patients with high-grade brain tumors that have relapsed or progressed after standard treatment. -
May 4, 2026Pamplona/MadridIn recruitmentEarly phase
BAY 3547926/ 22262 First human trial to assess the safety and efficacy of BAY 3547926 in participants with advanced liver cancer.
The purpose of this trial is to determine whether the new drug BAY 3547926 can be safely administered to participants, to identify the optimal dose, and to investigate how this new drug works in participants with advanced hepatocellular carcinoma. -
April 22, 2026MadridIn recruitmentEarly phase
PHN-012-001 Clinical trial of PHN-012 in patients with advanced solid tumors.
The primary objective is to determine the MTD or MAD for intravenous PHN-012 monotherapy and to evaluate its safety and tolerability. -
April 21, 2026Pamplona/MadridIn recruitment
M25-586 A clinical trial to evaluate the efficacy and safety of etentamig and daratumumab (etentamig) compared with daratumumab, lenalidomide, and dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are not eligible for transplantation.
The objective of this study is to determine whether etentamig is safe and to identify the optimal dose of etentamig when combined with daratumumab in participants with newly diagnosed multiple myeloma (NDMM) who are not eligible for transplantation.